Betty Tijms, PhD, VU University Medical Center Amsterdam, Amsterdam, Netherlands, shares her thoughts on the potential of studying the proteome in Alzheimer’s disease (AD). While our understanding of the proteome in AD is at an early stage, including how it changes across the disease spectrum and how to can be used for prediction and prognostication, it is hoped that these insights could lead to the emergence of novel biomarkers and inform personalized medicine strategies for patients. Recent work from Dr Tijms and her team has identified three distinct molecular subgroups in AD, based on cerebrospinal fluid proteomics. The protein expression changes seen in individuals with AD versus controls reflect alterations in biological processes that can give clues to develop personalized treatments. Additionally, by defining more specific subgroups within AD, we may be able to better select patients most likely to respond to a given therapeutic approach, improving the power of clinical trial to detect beneficial effects. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
